Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report
Crossref DOI link: https://doi.org/10.1186/s12885-016-2342-x
Published Online: 2016-05-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Henderson, Sara L.
Teft, Wendy A.
Kim, Richard B.
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-89753)
Drug Safety and Effectiveness Network (DSEN-PREVENT FRN-117588)